Regencell Bioscience Holdings (RGC) Gains from Investment Securities (2023)
Regencell Bioscience Holdings (RGC) reported Gains from Investment Securities of $6.7 million for Q2 2023.
Regencell Bioscience Holdings (RGC) Gains from Investment Securities (2023) Analysis & Trends
Regencell Bioscience Holdings has reported Gains from Investment Securities for 1 years, with the latest figure at $6.7 million in Q2 2023.
- For the quarter ending Q2 2023, Gains from Investment Securities changed N/A year-over-year to $6.7 million; the trailing twelve-month figure through Jun 2023 stood at $6.7 million (changed N/A YoY), and the FY2025 full-year result was $778625.0, up 994.77% from the prior year.
- Gains from Investment Securities for Q2 2023 stood at $6.7 million.
- The five-year high for Gains from Investment Securities was $6.7 million in Q2 2023, with the low at $6.7 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Regencell Bioscience Holdings | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 6.66 Mn |
| Jun 30, 2023 | 6.66 Mn |